Method and composition for improving fertility health in female and male animals and humans

Abstract

In a new pharmaceutical combination, the herb, Vitex agnus - castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.

Claims

I claim: 1 . A pharmaceutical composition having fertility promoting activity in females comprising in combination components in effective amounts of Vitex agnus - castus (chasteberry), antioxidants, including green tea, vitamin E or selenium, L-arginine, folic acid, vitamins B6 and B12, iron, zinc and magnesium. 2 . The pharmaceutical composition of claim 1 , wherein the components are present in the proportion in parts by weight of about 2 to 20% Vitex agnus - castus (chasteberry), about 5 to 50% antioxidants, including green tea, vitamin E or selenium, about 10 to 80% L-arginine, an amino acid, about 0.001 to 1% folic acid, about 0.001 to 1% vitamins B6 and B12, about 0.1 to 10% iron, about 1 to 10% zinc and about 5 to 50% magnesium. 3 . The pharmaceutical composition of claim 1 , wherein the components are present in the proportion in parts by weight of about 4 to 20% Vitex agnus - castus (chasteberry), about 20 to 50% antioxidants, including green tea, vitamin E or selenium, about 40 to 80% L-arginine, an amino acid, about 0.1 to 1% folic acid, about 0.3 to 1% vitamins B6 and B12, about 2 to 10% iron, about 1 To 10% zinc, and about 20 to 50% magnesium. 4 . A pharmaceutical composition having fertility promoting activity in females comprising in combination components in effective amounts of the following components present in proportions in parts by weight of about 1 to 20% Vitex agnus - castus (chasteberry), about 5 to 50% antioxidants, including green tea, vitamin E or selenium, about 10 to 80% L-arginine, an amino acid, about 0 to 1% folic acid, about 0 to 1% vitamins B6 and B12, about 0 to 10% iron, about 0 to 10% zinc, and about 0 to 50% magnesium. 5 . A pharmaceutical composition having fertility promoting activity in males comprising in combination components in effective amounts vitamins C and E, selenium, ferulic acid, zinc and B vitamins. 6 . The pharmaceutical composition of claim 5 , further comprising in combination with the other components an effective amount of L-carnitine. 7 A pharmaceutical composition of claim 6 , wherein the components are present in the proportion in pans by weight of about 20 to 80% L-carnitine, about 5 to 25% vitamins C and E, about 0.1 to 10% coenzyme Q10, about 0.001 to 1% selenium, about 0.2 to 20% ferulic acid, about 0.1 to 2% ferulic, and about 0.001 to 1% B vitamins. 8 . A pharmaceutical composition of claim 5 , wherein the components are present in the proportion in parts by weight of about 5 to 50% vitamins C and E, about 0.1 to 15% coenzyme Q10, about 0.001 to 1% selenium, about 0.2 to 20% ferulic acid, about 0.1 to 15% zinc, and about 0.01 to 1% B vitamins. 9 . A pharmaceutical composition of claim 5 , wherein the components are present in the proportion in parts by weight of about 60% L-carnitine, about 25% vitamins C and E, about 6% ferulic acid, about 5% zinc and B vitamins, about 5% coenzyme coQ10, and
BACKGROUND OF THE INVENTION [0001] Because of delayed child bearing, unhealthy diets and use of tobacco, caffeine, alcohol, drugs and environmental contaminants, difficulties in conceiving have been experienced. [0002] Needs exist for pharmaceutical compounds that improve fertility in both women and men. SUMMARY OF THE INVENTION [0003] This invention provides combinations of bioeffecting compounds for promoting fertility in men and women. The combinations include nutritional components that benefit fertility health. All the components have been studied separately, to determine their individual efficacy. The invention provides the first products to put these components together synergistically in women's and men's formulations. [0004] As many as 15% of couples in the U.S. have difficulty conceiving a child. In about one third of these cases, it is the man that is infertile; in another third, the female has fertility issues. The remaining is due to a combination of male and female fertility issues, or unknown causes. In many of these cases, causes of infertility are treatable. Nutritional and lifestyle changes should be the first step to increasing chances for conception. Smoking and caffeine, drug and alcohol consumption, environmental toxicants, and stress are related to infertility in men and women. Reproductive organs are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. A balanced, nutritional diet, and nutritional supplements with high antioxidant content can help reverse some of that damage. In women, hormone balance is critical to monthly ovulation and development of the corpus luteum (an ovarian follicle that release progesterone after release of the egg to prepare the uterus for implantation). [0005] These and further and other objects and features of the invention are apparent in the disclosure, which include the above ongoing written specification with the claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0006] The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in women. The invention provides a scientifically validated herbal/nutritional blend for women to improve infertility by helping to regulate the menstrual cycle and correct hormone imbalance (corpus luteum insufficiency) without increased chances of multiple births associated with drug therapy. The combination of amino acids, herbs, vitamins and minerals improves overall health and helps with many of the deficiencies that decrease fertility. [0007] The herb, Vitex agnus - castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. [0008] The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in men. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm. [0009] The invention provides synergistic action of the combinations. [0010] The two dietary supplements in male and female formulas are useful for men and women. Preferably, the distinct combinations are taken by both members of a couple in which the female age is between 21 and 46. The distinct combinations are useful for couples who have tried for 6 months or more, up to three years, to become pregnant without success. Preferably, patients take 2-4 capsules per day of the distinct formulas for three months. In women it is useful to record their basal temperature daily using thermometers and charts and to have their blood drawn for progesterone analysis at day 18-22 of the first menstrual cycle prior to taking the supplement. For men, it is useful to submit a sperm sample at the same time for analysis of count and motility. Prior to submitting sperm samples, 2-4 days abstinence is suggested for best results. No fevers over 101 degrees in the three months prior to taking the new combinations should be encountered. It is useful to repeat the analyses during the fourth menstrual cycle of the study. The first month is needed to develop baselines, followed by three months of taking the combinations product or placebo. [0011] Preferred ranges of the combinations considered in percent by weight are: Components Minimum % Maximum % Women's formula 2 10 Vitex (chasteberry) 2 10 L-arginine 40 60 Green tea 5 20 Vitamin B 5 20 Selenium .01  1 Vitamins B6, B12 .01  1 Folic acid .01  1 Iron .1  5 Magnesium 10 40 Zinc 1  5 Men's Formula L-carnitine 40 70 Ferulic acid in Dong Quai .1 10 Vitamins C and E 10 30 Coenzyme coQ10 .1  5 Selenium .01  1 Zinc .1 10 B vitamins .001  1 [0012] Acceptable ranges of womens' and mens' formulations are: Components Minimum % Maximum % Women's Formula 1 20 Vitex (chasteberry) 20 70 L-arginine 0 30 Green tea 0 30 Vitamin B 0  2 Selenium 0  2 Vitamins B6, B12 0  2 Folic acid 0  1 Iron 0  7 Magnesium 5 50 Zinc 01 10 Men's Formula L-carnitine 20 80 Ferulic acid in Dong Quai 0 20 Vitamins C and E .01 40 Coenzyme coQ10 .01 10 Selenium 0  3 Zinc .01 15 B vitamins 0  2 [0013] Examples of useful formulations in percent by weight are: Components Women's formula Vitex (chasteberry)  5 L-arginiue  50 Green tea  11 Vitamin B  11 Selenium   .03 Vitamins B6, B12   .03 Folic acid   .03 Iron  1 Magnesium  20 Zinc  1 100% Men's Formula L-carnitine  60 Ferulic acid in Dong Quad  6 Vitamins C and B  25 Coenzyme coQ10  3 Selenium  6 Zinc  5 B vitamins  4 100% [0014] While the invention has been described with references to specific embodiments, modifications and variations of the invention may be constructed without departing from the scope of the invention, which is defined in the following claims.

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (53)

    Publication numberPublication dateAssigneeTitle
    US-5439938-AAugust 08, 1995The Johns Hopkins UniversityTreatments for male sexual dysfunction
    US-5157022-AOctober 20, 1992Adrian BarbulMethod for reducing blood cholesterol using arginine
    US-6156802-ADecember 05, 2000Kaneka CorporationCholesterol-lowering composition
    US-5106836-AApril 21, 1992Clintec Nutrition Co.Enteral diet
    US-4954526-ASeptember 04, 1990The United States Of America As Represented By The Department Of Health And Human ServicesStabilized nitric oxide - primary amine complexes useful as cardiovascular agents
    US-5626883-AMay 06, 1997Metagenics, Inc.Ascorbic acid compositions providing enhanced human immune system activity
    US-5500266-AMarch 19, 1996Eastman Kodak CompanySpin-coating compensation for an optical storage medium with a substrate groove profile gradient
    US-6007824-ADecember 28, 1999Duckett; Melvin J., Moore; KyleNatural composition and method for the treatment of sexual dysfunction
    US-5545414-AAugust 13, 1996Abbott LaboratoriesCholesterol lowering food product
    US-4957938-ASeptember 18, 1990Abbott LaboratoriesNutritional formulation for the treatment of renal disease
    US-5464644-ANovember 07, 1995Kellogg CompanyReady-to-eat-cereal containing psyllium and use thereof for lowering cholesterol levels
    US-5852058-ADecember 22, 1998The Board Of Trustees Of The Leland Stanford Junior UniversityIntramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
    US-5650418-AJuly 22, 1997Therapy 2000Therapeutic lysine salt composition and method of use
    US-5041429-AAugust 20, 1991Sanwa Kagaku Kenkyusho Co., Ltd.Cell activators, circulatory ameliorators and edible compositions
    US-4168307-ASeptember 18, 1979Mitsubishi Chemical Industries Limited, Shosuke OkamotoN2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
    US-5543430-AAugust 06, 1996Kaesemeyer; W. H.Method and formulation of stimulating nitric oxide synthesis
    US-4920098-AApril 24, 1990Baxter International Inc.Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
    US-5262435-ANovember 16, 1993Merck & Co., Inc.Cholesterol lowering compounds
    US-5248688-ASeptember 28, 1993Dudrick Medical Research Fund I, Ltd.Method and substrate composition for treating atherosclerosis
    US-3015567-AJanuary 02, 1962Du PontProcess for enriching the l-lysine content of food and the resulting product
    US-5780039-AJuly 14, 1998Novartis Nutrition AgOrally-ingestible nutrition compositions having improved palatability
    US-5897864-AApril 27, 1999Cohen; Alan J.Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
    US-5036052-AJuly 30, 1991Morishita Pharmaceutical Co., Ltd., Ajinomoto Co., Inc.Amino acid nutrient compositions
    US-5278189-AJanuary 11, 1994Rath Matthias W, Pauling Linus CPrevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
    US-5221668-AJune 22, 1993Abbott LaboratoriesNutritional product for trauma and surgery patients
    US-5034377-AJuly 23, 1991Montefiore Hospital Association Of Western PennsylvaniaAqueous nutrient compositions comprising oligopeptides
    US-5576287-ANovember 19, 1996Wake Forest UniversityMethod for treating acute renal disease and failure
    US-5730987-AMarch 24, 1998Omar; Lotfy IsmailMedication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
    US-3360374-ADecember 26, 1967Courtland LabProcess for making a dietary food product
    US-5631031-AMay 20, 1997Meade; Thomas L.Water-insoluble amino acid salt
    US-4154813-AMay 15, 1979Israel KleinbergMeans and method for improving natural defenses against caries
    US-5296246-AMarch 22, 1994Fujix CorporationActive amino acid Ca, beverages containing same, and process for their production
    US-5767160-AJune 16, 1998Notol, Inc.Method and formulation of stimulating nitric oxide synthesis
    US-3970750-AJuly 20, 1976Sandoz, Inc.Effervescent potassium chloride composition
    US-5326569-AJuly 05, 1994Abbott LaboratoriesMedical foods for the nutritional support of child/adult metabolic diseases
    US-5288490-AFebruary 22, 1994Temple University Of The Commonwealth System Of Higher EducationThrombus-targeted complexes of plasminogen activator and fibrin fragments
    US-5385940-AJanuary 31, 1995The General Hospital CorporationTreatment of stroke with nitric-oxide releasing compounds
    US-4340592-AJuly 20, 1982Adibi Siamak ANutrient compositions and method of administering the same
    US-2878124-AMarch 17, 1959Bayer AgFood additives
    US-5411956-AMay 02, 1995Nisshin Flour Milling Co., Ltd.Lipolytic enzyme inhibitors
    US-4388325-AJune 14, 1983Societa' Italo-Britannica L. Manetti-H. Roberts & C.L-Arginine D,L-pyroglutamate as a pharmaceutical agent having an activity at the neuro-endocrinal level
    US-5380945-AJanuary 10, 1995Abbott LaboratoriesGuanidino compounds as regulators of nitric oxide synthase
    US-5334617-AAugust 02, 1994The Rockefeller University, Alteon Inc.Amino acids useful as inhibitors of the advanced glycosylation of proteins
    US-5385937-AJanuary 31, 1995Brigham & Women's HospitalNitrosation of homocysteine as a method for treating homocysteinemia
    US-5374651-ADecember 20, 1994Board Of Regents, The University Of Texas SystemMethods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
    US-5576351-ANovember 19, 1996Mcgaw, Inc.Use of arginine as an immunostimulator
    US-5364644-ANovember 15, 1994Board Of Regents, The University Of Texas SystemFormula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders
    US-5594032-AJanuary 14, 1997Gonzalez-Cadavid; Nestor F., Rajfer; JacobAmelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
    US-4900566-AFebruary 13, 1990The Howard FoundationConfectionary product and a process for producing the same
    US-5171217-ADecember 15, 1992Indiana University FoundationMethod for delivery of smooth muscle cell inhibitors
    US-5861168-AJanuary 19, 1999The Board Of Trustees Of The Leland Stanford Junior UniversityIntramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
    US-5523087-AJune 04, 1996Bio-Virus Research IncorporatedPharmaceutical compositions for the treatment of diabetic male sexual dysfunction
    US-5032608-AJuly 16, 1991Dudrick Stanley JMethod and substrate composition for treating atherosclerosis

NO-Patent Citations (0)

    Title

Cited By (1)

    Publication numberPublication dateAssigneeTitle
    US-2013136724-A1May 30, 2013Kaneka CorporationPig feed, and method for feeding same